The Algorithmic Mirage: How AI's Promise in Drug Discovery Risks Inflating Expectations
I. Introduction: The Double-Edged Scalpel of AI in Drug Discovery
The relentless pursuit of new medicines remains a cornerstone of
Magic Bullets, Reloaded: The Global Rise of Antibody–Drug Conjugates
The Return of the “Magic Bullet”
In 1908, the German scientist Paul Ehrlich coined the term “Zauberkugel” – magic bullet – envisioning
Pharma’s Perennial Patent Cliff: Crisis or Routine Cycle?
The Next Big Patent Cliff Looms
Pharmaceutical investors are once again bracing for what industry insiders ominously dub a “patent
Royalty Financing Rescues Biopharma: A H1 2025 Global Analysis
The first half of 2025 saw an unprecedented surge in royalty-based financings and structured revenue deals across the biopharmaceutical sector.
High Ideals, Inside Deals: Biotech’s Lab Leaks of the Financial Kind
Trials, Errors, and Timely Trades
In the rarefied world of biotech, miracles in the lab often meet murkier practices in
THE PANEL DISCUSSION FROM HELL
A Corporate Pastoral in Four Acts
By one who has seen the lanyards and despaired.
DRAMATIS PERSONAE
* CLAIRE DU VAGUE
South Korea’s Innovation Leadership at a Crossroads (2025 and Beyond)
South Korea’s rise from a war-torn nation in the 1950s to a global technological powerhouse is nothing short of
The Polygenic Prophet: Hype and Reality of Polygenic Risk Scores
Polygenic risk scores (PRS) are the latest oracle in healthcare’s quest to predict fate. The basic idea sounds beguilingly
The Outsourcing Hangover: CROs, CDMOs and a Capacity Conundrum
“Excess capacity” – not a phrase one expects to hear in a high-growth industry riding on the coattails of pharmaceutical innovation.
In Praise of Discomfort: Why Less Government Funding Might Be Good for Science
There are few things more sacred in biotech than the sanctity of government grants. At the heart of this cathedral
